fluvoxamine (Q409236)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

chemical compound

Luvox®
U-23000
Fluvoxamine
Fluvoxaminum
Fluvoxamina

Language	Label	Description	Also known as
English	fluvoxamine	chemical compound	Luvox® U-23000 Fluvoxamine Fluvoxaminum Fluvoxamina

Statements

type of chemical entity

0 references

2-[[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine

1 reference

based on heuristic

inferred from InChIKey

0 references

chemical structure

Fluvoxamine.svg
512 × 395; 4 KB

0 references

318.156 dalton

1 reference

language of work or name

fluvoxamine (English)

19 October 2016

chemical formula

C₁₅H₂₁F₃N₂O₂

1 reference

language of work or name

fluvoxamine (English)

19 November 2016

canonical SMILES

COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F

1 reference

language of work or name

fluvoxamine (English)

19 November 2016

isomeric SMILES

COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F

1 reference

language of work or name

fluvoxamine (English)

19 November 2016

defined daily dose

0.1 gram

route of administration

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=N06AB08

active ingredient in

1 reference

14 February 2018

World Health Organisation international non-proprietary name

fluvoxamine (English)

1 reference

language of work or name

fluvoxamine (English)

19 October 2016

medical condition treated

anxiety disorder

1 reference

language of work or name

13 December 2016

1 reference

language of work or name

13 December 2016

neurotic disorder

1 reference

language of work or name

13 December 2016

obsessive-compulsive disorder

2 references

language of work or name

13 December 2016

Drug Indications Extracted from FAERS

2 October 2018

obsessive-compulsive disorder

19 December 2007

Food and Drug Administration

1 reference

Inxight: Drugs Database

2 November 2018

https://drugs.ncats.io/drug/O4L1XPO44W

http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021519lbl.pdf

mental depression

0 references

significant drug interaction

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

High-priority drug–drug interactions for use in electronic health records

tranylcypromine

1 reference

High-priority drug–drug interactions for use in electronic health records

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

retroperitoneal hemorrhage

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

theophylline monohydrate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

theophylline monohydrate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

theophylline monohydrate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

theophylline monohydrate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

mental status change

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(−)-selegiline

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

urinary retention

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

urinary retention

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

urinary retention

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

intention tremor

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

intention tremor

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

solute carrier family 6 member 4

subject has role

enzyme inhibitor

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

LiverTox likelihood score

LiverTox toxicity likelihood category D

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Fluvoxamine

2 February 2018

subject has role

selective serotonin reuptake inhibitor

2 references

5 March 2018

Medical Subject Headings

MeSH descriptor ID

15 March 2018

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

second-generation antidepressive agents

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

cytochrome P-450 CYP1A2 Inhibitors

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

cytochrome P-450 CYP2C19 Inhibitors

1 reference

Medical Subject Headings

MeSH descriptor ID

15 March 2018

fluvoxaMINE

has characteristic

Tall Man lettering

Institute for Safe Medication Practices

1 reference

https://www.ismp.org/recommendations/tall-man-letters-list

2 September 2022

Commons category

Fluvoxamine

0 references

Identifiers

InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+

1 reference

language of work or name

fluvoxamine (English)

19 November 2016

CJOFXWAVKWHTFT-XSFVSMFZSA-N

2 references

language of work or name

fluvoxamine (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

2 references

Global Substance Registration System

language of work or name

fluvoxamine (English)

19 November 2016

CJOFXWAVKWHTFT-XSFVSMFZSA-N

CAS Common Chemistry

9 April 2021

https://commonchemistry.cas.org/detail?cas_rn=54739-18-3

1 reference

language of work or name

Fluvoxamine (English)

19 November 2016

2 references

language of work or name

fluvoxamine (English)

19 November 2016

matched by identifier from

CJOFXWAVKWHTFT-XSFVSMFZSA-N

Reaxys registry number

5583954

1 reference

language of work or name

fluvoxamine (English)

19 October 2016

mapping relation type

2 references

language of work or name

FLUVOXAMINE (English)

19 November 2016

matched by identifier from

International Chemical Identifier

InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+

1 reference

language of work or name

FLUVOXAMINE (English)

19 November 2016

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

CJOFXWAVKWHTFT-XSFVSMFZSA-N

UniChem compound ID

1 reference

MassBank accession ID

0 references

splash10-00di-9033000000-d6a8b06f446107932c1c

0 references

DSSTox substance ID

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

matched by identifier from

CJOFXWAVKWHTFT-XSFVSMFZSA-N

DSSTOX compound identifier

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

(E)-(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine (English)

CAS no.: 54739-18-3 (English)

ECHA Substance Infocard ID

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

27 December 2018

(E)-(2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine (English)

CAS no.: 54739-18-3 (English)

1 reference

language of work or name

Fluvoxamine (English)

publication date

17 November 2015

Guide to Pharmacology Ligand ID

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

fluvoxamine (English)

19 November 2016

MeSH descriptor ID

subject named as

Fluvoxamine

0 references

MeSH concept ID

0 references

D02.092.570.665.250

0 references

1 reference

Global Substance Registration System

language of work or name

fluvoxamine (English)

19 November 2016

1 reference

matched by identifier from

CJOFXWAVKWHTFT-XSFVSMFZSA-N

2 references

Global Substance Registration System

language of work or name

fluvoxamine (English)

19 November 2016

matched by identifier from

CJOFXWAVKWHTFT-XSFVSMFZSA-N

MedlinePlus drug identifier

0 references

1 reference

Global Substance Registration System

language of work or name

fluvoxamine (English)

19 November 2016

Probes And Drugs ID

0 references

1 reference

1 reference

language of work or name

fluvoxamine (English)

19 October 2016

1 reference

language of work or name

fluvoxamine (English)

19 October 2016

0 references

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

1 reference

9 July 2020

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

PDB structure ID

1 reference

Protein Data Bank

PDB structure ID

language of work or name

4ENH (English)

19 October 2016

1 reference

Protein Data Bank

PDB structure ID

language of work or name

4MM9 (English)

19 October 2016

1 reference

Römpp online ID

1 reference

imported from Wikimedia project

German Wikipedia

Store medisinske leksikon ID

mapping relation type

subject named as

fluvoksamin

1 reference

Great Norwegian Encyclopedia

5 June 2020

1 reference

Global Substance Registration System

language of work or name

fluvoxamine (English)

19 November 2016

WikiProjectMed ID

0 references

Sitelinks

Wikipedia(30 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Fluvoxamine

Retrieved from "https://www.wikidata.org/w/index.php?title=Q409236&oldid=2237824006"